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Abstract 
Introduction: To characterize extended-spectrum β-lactamases (ESBLs) and plasmid-mediated quinolone resistance (PMQR) genes in 
Escherichia coli isolates obtained from extra-intestinal samples in three Uruguayan hospitals. 
Methodology: Fifty-five ESBL-producing E. coli isolates were studied. Virulence genes, ESBLs, and PMQR genes were detected by 
polymerase chain reaction.  ESBL-producing isolates were compared by pulsed-field gel electrophoresis. Multi-locus sequence typing was 
also performed on 13 selected isolates. 
Results: Thirty-seven isolates harbored blaCTX-M-15 (67.3%), eight blaCTX-M-2 (14.6%), five blaCTX-M-14 (9.1%), three carried both blaCTX-M-2 
and blaCTX-M-14, one blaCTX-M-9, and one blaCTX-M-8.  Among the CTX-M-15 producers, 92% belonged to sequence types ST131 and ST405, 
and carried aac(6’)Ib-cr as well. Isolates harboring blaCTX-M-2, blaCTX-M-14, blaCTX-M-9, or blaCTX-M-8 were found to be genetically unrelated. 
Conclusions: The successful dissemination of CTX-M-15-producing E.coli isolates seems to be linked to the spreading of high-risk clones 
and horizontal gene transfer. A trade-off between carrying more antibiotic resistance and less virulence-related genes could partially account 
for the evolutionary advantages featured by successful clones. 
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Introduction 
Escherichia coli is a versatile pathogen, 
responsible for intestinal and extra-intestinal 
infections. Urinary tract infections (UTIs), sepsis, 
bacteremia, and meningitis are among the latter. The 
ability of E. coli to cause extra intestinal infections 
relies on a number of virulence factors that include 
adhesins, tissue-damaging effectors, and factors 
conferring resistance to the bactericidal activity of 
serum, among others [1,2]. 
Identification of extra-intestinal pathogenic E. coli 
strains (ExPEC) can be achieved by detecting at least 
two of the following genes: papA, papC, sfa/foc, 
afa/dra, iutA, or kpsM II [3]. The occurrence of these 
genes is associated with strains belonging to 
phylogenetic groups B2 and D (associated with 
ExPEC), and less frequently with groups A and B1, 
corresponding to commensal E. coli strains [4]. 
The emergence of successful clones such as E. coli 
ST131 or clonal group A (CGA), both distributed 
worldwide, is a clear example of coexistence between 
antibiotic multiresistance and virulence factors [5-7].  
Co-resistance in E. coli to oxyiminocephalosporins 
(especially mediated by ESBLs) and quinolones is an 
increasing event worldwide, particularly in Latin 
America [8]. Yet, the available information concerning 
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the dissemination of different clones and/or the 
presence of virulence factors is scarce in South 
America [9,10]. 
In Uruguay, the occurrence of E. coli strains 
producing PER-2, CTX-M-15, SHV-5, or CTX-M-2 
ESBLs, as well as plasmid-mediated quinolone 
resistance genes (PMQR) linked to CTX-M-15, has 
already been reported [11-14]. We recently issued the 
first report in Latin America of a non-ExPEC strain 
harboring CTX-M-19 [15]; nevertheless there is no 
information so far that relates virulence factors in 
ExPEC, ESBLs, and PMQR among the circulating 
clones.  
In the present work, we describe the ESBLs 
present in E. coli strains obtained from extra-intestinal 
samples from three hospitals in Uruguay. 
 
Methodology 
Bacterial isolates 
Fifty-five ESBL-producing extra-intestinal E. coli 
isolates were obtained from three Uruguayan hospitals 
located in two different cities, between 1 March 2010 
and 28 February 2011. Each isolate was designated 
with letters E, C, or HP according to the hospital of 
origin. Thirty-six isolates were recovered from urine, 
seven from blood, five from skin lesions, two from 
abscesses, three from respiratory samples, and two 
from peritoneal fluid samples. 
 
Antimicrobial susceptibility and detection of extended-
spectrum β-lactamases (ESBLs) 
Bacterial identification and antibiotic susceptibility 
tests were performed using the VITEK2 Compact 
system (bioMérieux, Marcy l’Étoile, France). Every 
isolate displaying minimum inhibitory concentration 
(MIC) values to cefotaxime and/or ceftazidme and/or 
cepefime > 1 µg/mL underwent ESBL screening and 
confirmatory tests using ceftazidime and cefotaxime 
(30 µg) alone and combined with 10 µg of clavulanate, 
performed by disk diffusion as suggested by Clinical 
Laboratory Standards Institute (CLSI) guidelines [16]. 
MIC values to ceftazidime, cefotaxime, and 
ciprofloxacin were confirmed by Etest (bioMérieux, 
Marcy l’Étoile, France), following the manufacturer’s 
instructions. 
 
Characterization of ESBL and PMQR genes 
Isolates with positive ESBL-screening results were 
further analyzed by polymerase chain reaction (PCR) 
for the presence of blaCTX-M, blaTEM, blaPER-2, and 
blaSHV genes using specific primers [11]; PCR 
products were sequenced on both strands using the 
same primers.  
The occurrence of genes qnrA, qnrB, qnrC, qnrD, 
qnrS, and qepA was also screened by PCR, in isolates 
with MIC to nalidixic acid > 2 µg/mL [11]. Strains 
displaying MIC values to amikacin > 2 µg/mL were 
analyzed for the presence of aac(6′)Ib and the cr 
variant [11]. 
 
Multi-locus sequence typing (MLST), determination of 
CGA, and PFGE 
MLST was performed on selected isolates, 
representative of the most frequent pulsetypes, by gene 
amplification and sequencing of seven housekeeping 
genes (adk, fumC, gyrB, icd, mdh, purA, and recA), 
according to the protocol and primers specified at the 
E. coli MLST web site 
(http://mlst.ucc.ie/mlst/dbs/Ecoli). 
XbaI PFGE analysis was performed as previously 
described [17]. Additionally, CGA was determined for 
isolates characterized by MLST and belonging to 
phylogenetic group D by single-nucleotide 
polymorphisms (SNPs) analysis of fumC, as described 
by Johnson et al. [18]. PFGE profiles were analyzed 
with BioNumerics fingerprinting software (Applied 
Maths, St-Martens-Latem, Belgium). Dendrograms 
were generated using the unweighted pair-group 
method (UPGMA) using arithmetic averages, based on 
the Dice similarity coefficient, with a 2.0% band 
position tolerance. PFGE profiles sharing > 85% 
similarity were considered to be genetically related 
[19]. 
 
Transfer of ESBL, conjugation assays, and plasmid 
characterisation 
Twenty-five isolates representative of all 
pulsetypes were selected for conjugation and plasmid 
characterization. Conjugation assays were carried out 
using rifampicin-resistant E. coli J53-2 strain as 
recipient. Transconjugants were selected on 
MacConkey agar plates (Oxoid, Basingstoke, UK) 
supplemented with rifampicin (150 mg/L) (Sigma-
Aldrich St. Louis, USA) and ceftriaxone (1 mg/L) 
(Sigma-Aldrich St. Louis, USA) [20]. 
Conjugative plasmid incompatibility groups (Inc) 
and addiction systems were determined by PCR-based 
replicon-typing according to Carattoli et al. and Mnif 
et al., respectively, using genomic DNA obtained from 
transconjugants as a template [21,22]. 
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Phylogenetic group and virulotyping 
Classification of isolates into phylogenetic groups 
was determined by PCR as previously described [4], 
based on the presence or absence of three DNA 
fragments: chuA–, yjaA, and Tspe4.C2. Additionally, 
the sub-grouping scheme proposed by Branger et al. 
[23] was used. Briefly, the absence of the three DNA 
fragments corresponds to subgroup A0, whereas the 
occurrence of only yjaA corresponds to A1; on the 
other hand, B22 corresponds to the occurrence of chuA 
and yjaA, and B23 is defined by the presence of the 
three DNA fragments. Finally, subgroup D1 features 
the presence of only chuA, whereas subgroup D2 
features chuA and Tspe4.C2. 
Detection of virulence-related genes was 
performed in two stages. First, all isolates underwent 
PCR virulence screening (VS) as previously described 
by Johnson et al [3]. 
Next, isolates carrying two or more of papA, papC, 
sfa/foc, afa/dra, iutA, or kpsM II genes (i.e., VS+) 
were further examined by multiplex PCR for another 
25 virulence-related genes, as described by Johnson et 
al. [1]. 
 
Results 
The 55 isolates under study were phenotypically 
identified as ESBL-producers; however, the proportion 
of isolates resistant to cefotaxime or to ceftazidime 
was dissimilar. 
According to the CLSI interpretative criteria, 
100% of the isolates were resistant to cefotaxime 
(MIC50 = 64 µg/mL, MIC90 ≥ 256 µg/mL), whereas 
only 40% (22) were resistant to ceftazidime (MIC50 = 
2 µg/mL, MIC90 = 32 µg/mL). On the other hand, 
50/55 (90.9%) were resistant to ciprofloxacin (Figure 
1, Table 1). 
The 55 ESBL-producing isolates were distributed 
in 12 different resistance patterns; (Table 1) 
nevertheless, 39/55 (70.9%) were clustered in three 
major profiles (Table 1). 
All of the isolates were susceptible to carbapenems 
(data not shown). 
 
Figure 1. Main features of 55 E. coli strains studied in this work. 
Black: positive; grey: negative; white: not determined. a Sequencetype (ST) other than ST131 and ST405 were depicted in this column. 
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Detection of ESBLs and transferable quinolone 
resistance 
A total of 58 ESBL genes were detected among the 
55 ESBL-producing isolates. Thirty-seven isolates 
(67.3%) carried blaCTX-M-15, eight (14.6%) carried 
blaCTX-M-2, five (9.1%) carried blaCTX-M-14, three carried 
both blaCTX-M-2 and blaCTX-M-14 (isolates C54, C66, and 
E69), one isolate carried blaCTX-M-8, and another single 
isolate carried blaCTX-M-9 (Figure 1). Conversely, no 
blaTEM, blaSHV, or blaPER-2 ESBL genes were detected.  
Fifty of the ESBL-producing isolates were also 
resistant to ciprofloxacin, 35 of which harbored 
aac(6’)Ib-cr (33 carried blaCTX-M-15 and two carried 
blaCTX-M-14). Additionally, qnrA was detected in a 
single isolate, along with blaCTX-M-9. Furthermore, 
qnrB was detected along with blaCTX-M-8; however, in 
both cases, MIC values to ciprofloxacin were within 
the susceptibility range defined by the CLSI (Figure 
1). No qnrC, qnrD, qnrS, or qepA genes were detected. 
 
Clonal relationship 
PFGE assays were performed on all ESBL-
producing isolates; four of them were untypeable 
(three CTX-M-2 producers and one CTX-M-15 
producer). 
PFGE analysis of blaCTX-M-15-bearing isolates 
indicated that they were clustered in five pulsetypes; 
two major pulsetypes, named A and B, accounted for 
20 and 13 isolates, respectively, whereas pulsetypes C 
and D comprised two isolates each, and pulsetype E 
included a single isolate (Figure 2).  
On the other hand, isolates carrying blaCTX-M-2, 
blaCTX-M-14, blaCTX-M-9, and blaCTX-M-8 belonged to 
different pulsetypes, named F through O (Figure 2). 
MLST analysis showed that all of the isolates in 
pulsetype A belonged to sequence type ST131, 
whereas isolates in pulsetype B belonged to ST405.  
Isolates belonging to ST131 were detected in the 
three hospitals included in this study and were 
recovered from various sources (urine, blood, surgical 
wound infections, and peritoneal fluid).  
Similarly, isolates belonging to ST405 were only 
recovered in two hospitals (both located in the capital 
city, Montevideo) from similar sources, including 
broncheoalveolar lavage, abscesses, and pleural fluid 
as well. 
Table 1. Antibiotics resistance profiles of 55 ESBL producers E. coli and distribution of mainly clones. 
Profile Antibiotype N PT/ST/ BLEE (n) 
1 OAkGNCS 6 B/405/CTX-M-15(4), A/131/CTX-M-15(1), NT/393/CTX-M-2 (1) 
2 OAkGNC 1 I/393/CTX-M-2(1) 
3 OAkNCS 12 A/131/CTX-M-15(11), D/ND/CTX-M-15(1) 
4 OGNCS 12 
B/405/CTX-M-15(6), A/131/CTX-M-15(1), K/ND/CTX-M-2(1), LL/ND/CTX-M-2,CTX-M-14(1), 
NT/ND/CTX-M-2(1), N/ND/CTX-M-14(1), D/ND/CTX-M-14(1) 
5 OGNC 2 E/ND/CTX-M-15(1), A/131/CTX-M-15(1) 
6 OGS 1 O/69/CTX-M-9(1) 
7 ONCS 15 
B/405/CTX-M-15(3), A/131/CTX-M-15(6), NT/ND/CTX-M-2(2), C/ND/CTX-M-15(1),  
I/ND/CTX-M-2(1),  G/ND/CTX-M-14(1), H/ND/CTX-M-14(1) 
8 ONC 2 F/1158/CTX-M-2(1),  F/3627/CTX-M-2(1) 
9 ONS 1 J/ND/CTX-M-14(1) 
10 ON 1 M/3555/CTX-M-8(1) 
11 OG 1 C/38/CTX-M-2,CTX-M-14(1) 
12 O 1 L/ND/CTX-M-2,CTX-M-14(1) 
O: oxyiminocephalosporins; Ak: amikacin; G: gentamicin; N: nalidixic acid; C: ciprofloxacin; S: sulfamethoxazole-trimethoprim; PT: pulsetype; ST: 
sequence type; N: number of isolates displaying each resistance profile, (n) number of isolates belonging to each clone within a particular resistance profile. 
 
 
Table 2. Correlation between MLST and fumC SNPs aimed at the detection of CGA in phylogenetic group D E. coli isolates 
MLST No. of isolates 
fumC SNPs  for nucleotidic residues 
270 271 288 
ST 38 1 A T C 
ST 69 1 A T T 
ST 393 2 G C C 
ST 405 13 G C C 
ST 1158 1 A T C 
ST3555 1 G C C 
ST3627 1 A T C 
Characters in boldface correspond to the only sequence type compatible with CGA, according to the SNP profile.  
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On the other hand, CTX-M-2-producing isolates 
were typed as ST393 (n = 2), ST38, ST1158, and 
ST3627, whereas CTX-M-9 and CTX-M-8-producing 
isolates were found to belong to ST69 and ST3555, 
respectively. 
 
Determination of clonal group A 
Phylogenetic group D included 21 isolates, 13 of 
which belonged to pulsetype B and ST405. 
Furthermore, another 6 isolates underwent MLST 
studies. Sequence analyses of fumC aimed at the 
detection of CGA showed that only a single isolate 
(HP21), belonging to ST69 and carrying blaCTX-M-
9/qnrA, displayed the SNP C288T (Table 2). 
 
Transfer of ESBL genes and plasmid characterization 
Twenty-five isolates representative of each 
pulsetype, as well as the four untypeable isolates, were 
selected for conjugation assays: seven isolates 
harboring blaCTX-M-15, eight blaCTX-M-2, five blaCTX-M-14, 
three isolates carrying both blaCTX-M-2 and blaCTX-M-14, 
one carrying blaCTX-M-9, and one with blaCTX-M-8 (Table 
3). 
  
Figure 2. PFGE patterns and main features of ESBL-producing ExPEC strains. 
PMQR: plasmid mediated quinolone resistance; PG: phylogenetic group; VS: virulence screening; WE: wound exudate; SWI: surgical wound infection; 
TA: tracheal aspirate; BAL: bronchoalveolar lavage; abd. absc: abdominal abscess. 
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  Table 3. Main features of the 25 selected extra-intestinal pathogenic E. coli and transconjugants strains under study 
Strain Resistance genes Pulsetype ST CTX CAZ CIP AK Inc Addiction system  
C05 blaCTX-M-2 F 3627 64 2 12 4   
E7 
blaCTX-M-14 
/aac(6’)Ib-cr 
N  8 1.5 ≥ 32 16   
TcE7 blaCTX-M-14 - - 8 1.5 0.03 0.38 I1 pndAC 
E13 blaCTX-M-15 C  64 16 ≥ 32 4   
TcE13 blaCTX-M-15 - - 24 8 .06 1 F -FIA-FIB vagCD/pemKI/ccdAB/srnBC 
E20 
blaCTX-M-15/ 
aac(6’)Ib-cr 
A 131 16 16 ≥ 32 8   
TcE20 
blaCTX-M-15/ 
aac(6’)Ib-cr 
- - 16 8 0.12 2 F-FIA-FIB vagCD/pemKI/ccdAB/srnBC 
E21 blaCTX-M-14 J  > 256 0.5 1 3   
TcE21 blaCTX-M-14 - - 16 2 0.015 0.5 I1 pndAC 
E32 blaCTX-M-2 NT ST393 128 4 ≥ 32 ≥ 32   
E35 
blaCTX-M-15/ 
aac(6’)Ib-cr 
B ST405 > 256 24 ≥ 32 6   
E38 blaCTX-M-2 I ST393 > 256 4 ≥ 32 24   
E44 blaCTX-M-2 K  48 3 ≥ 32 1,5   
TcE44 blaCTX-M-2 - - 32 3 0.015 0.125 F-FIB, A/C hok-sok 
E46 
blaCTX-M-15/ 
aac(6’)Ib-cr 
E  64 16 ≥ 32 8   
E47 blaCTX-M-14 G  2 0.125 8 3   
TcE47 blaCTX-M-14 - - 6 1 0.015 0.25 K, B/O  
E49 
blaCTX-M-15/ 
aac(6’)Ib-cr 
D  64 64 ≥ 32 16   
C53 blaCTX-M-15 NT  8 8 ≥ 32 32   
C54 blaCTX-M-2/14 L  > 256 2 0.03 3   
TcC54 blaCTX-M-14 - - 32 6 0.015 0.35 I1 pndAC 
C55 blaCTX-M-2 F ST1158 64 2 4 3   
E59 blaCTX-M-8/qnrB M ST3555 8 0.5 1 6   
TcE59 blaCTX-M-8 - - 2 0.75 0.015 0.125 I1 pndAC 
C66 blaCTX-M-2/14 LL  64 16 8 2   
TcE66 blaCTX-M-14 - - 12 1.5 0.015 0.25 F I1 pndAC/ hok-sok 
E69 blaCTX-M-2/14 C ST38 32 2 0.03 4   
TcE69 blaCTX-M-14 - - 16 1.5 0.015 0.38 F I1 pndAC/ hok-sok 
HP01 
blaCTX-M-14/ 
aac(6’)Ib-cr 
H Nd 8 1 ≥ 32 1   
TcHP01 blaCTX-M-14   8 2 0.015 0.25 I1 pndAC 
HP03 blaCTX-M-2 NT Nd 32 2 8 2   
HP06 blaCTX-M-14 D Nd 16 1.5 8 2 I1  
TcHP06 blaCTX-M-14 - - 8 1.5 0.008 0.125  pndAC 
HP13 blaCTX-M-15 A ST131 2 2 ≥ 32 16   
HP14 blaCTX-M-2 NT Nd 64 2 12 4   
HP15 blaCTX-M-2 I Nd 32 2 ≥ 32 4   
HP21 blaCTX-M-9/qnrA O ST69 16 3 0.12 8   
TcHP21 blaCTX-M-9 - - 4 1 0.03 0.25 HI1-HI2  
Tc: transconjugant; NT: untypeable; Nd: not determined; CTX: cefotaxime; CAZ: ceftazidime; CIP: ciprofloxacin; AK: amikacin; Inc: incompatibility group; 
Incompatibility group and addiction systems only were detected in transconjugants. 
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Thirteen transconjugants were obtained. All of the 
blaCTX-M-14, blaCTX-M-9, and blaCTX-M-8 genes were 
encoded in conjugative plasmids; however, only two 
blaCTX-M-15 alleles (carried by isolates E13 and E20, 
pulsetypes A and C, respectively) as well as a single 
blaCTX-M-2 allele (isolate E44, pulsetype K) were 
encoded in conjugative plasmids. 
Seven of the blaCTX-M-14 alleles were encoded in 
IncI1 plasmids featuring a pndAC addiction system. In 
contrast, plasmids carrying blaCTX-M-2 (IncF-FIB, 
IncA/C) and blaCTX-M-9 (IncHI1-HI2) featured no 
addiction systems. Nevertheless, both of the blaCTX-M-
15-bearing plasmids featured several addiction systems, 
specifically vagCD, pemKI, ccdAB, and srnBC (Table 
3). 
 
Phylogenetic group and virulotyping of ESBL-
producing strains 
Forty-one of the 55 ESBL-producing isolates 
belonged to phylogenetic groups B2 and D (B23 = 20; 
D2 = 13; D1 = 8). However, only 29 of such isolates 
were VS+, namely the twenty strains belonging to 
phylogenetic group B23 (pulsetype A, ST131, CTX-
M-15 producers), eight isolates belonging to 
phylogenetic group D1, and one isolate belonging to 
phylogenetic group A1 (Figure 1).  
Isolates belonging to phylogenetic group D1 were 
found to be genetically unrelated; five such isolates 
were CTX-M-2 producers and were typed as ST393 (n 
= 2), ST38, ST1158, and ST3627. Other D1 isolates 
included a CTX-M-9 and QnrA-producer (ST69), as 
well as another isolate belonging to the new sequence 
type ST3555, which harbored both qnrB and blaCTX-M-
8. 
Isolates carrying large numbers of virulence genes 
(between 9 and 10), namely isolates E38, E69, and 
HP21, belonged to phylogenetic group D1; 
nevertheless, they were not among the most 
disseminated strains. 
On the other hand, the 14 isolates belonging to 
phylogenetic group D2 and ST405 were VS-.  
 
Discussion 
In the present study, the 55 ESBL-producing 
isolates were distributed in 12 different resistance 
patterns, the most frequent being 
oxyiminocephalosporins / nalidixic acid / 
ciprofloxacin / sulfamethoxazole-trimethoprim (n = 
15), oxyiminocephalosporins / gentamicin / nalidixic 
acid / ciprofloxacin / sulfamethoxazole-trimethoprim 
(n = 12), and oxyiminocephalosporins / amikacin /  
nalidixic acid / ciprofloxacin / sulfamethoxazole-
trimethoprim (n = 12).  
Co-resistance to fluoroquinolones was observed in 
90.9% (50/55) of the studied isolates; co-resistance to 
sulfamethoxazole trimethoprim was detected in 85.5% 
(47/55), co-resistance to gentamicin in 41.8% (23/55), 
and co-resistance to amikacin in 34.5% (19/55).  
Recent studies have reported susceptibility results 
and molecular characterization of E. coli isolates in 
India, albeit with some differences; while co-
resistance levels to sulfamethoxazole-trimethoprim 
and to ciprofloxacin were similar (81.6% and 93.9%, 
respectively), co-resistance to amikacin was higher 
(57.1%), and resistance to carbapenems was even 
detected (20.4%) [24]. 
Sixty percent of the isolates (33/55) were clustered 
in two clones, namely B23-ST131 and D2-ST405. 
Accordingly, these clones accounted for 56.5% of co-
resistance to gentamicin (13/23 isolates) and 66% of 
co-resistance to ciprofloxacin (33/50); however, they 
were responsible for 84.2% of co-resistance to 
amikacin (16/19 isolates). 
Although both clones have been widely reported 
worldwide [25-28], their presence in South America is 
still scarcely reported [9,10,29]. 
In the present study, 41/55 isolates (74.5%) 
corresponded to phylogenetic groups B2 and D; 
nevertheless, only 28 (50.9%) could be classified as 
ExPEC based on VS. Additionally, all of the isolates 
corresponding to phylogenetic group B2 belonged to 
ST131. Our results are in accordance with those of 
Brisse et al., who found that CTX-M-production in 
ExPEC was exceptional in non-ST131 B2 strains [30]. 
Conversely, Roy et al. recently reported that over a 
third of CTX-M-15-producing E. coli B2 strains did 
not belong to ST131 [24]. These discrepancies 
highlight the importance of knowing the local 
epidemiology, in order to determine the circulating 
clones in each region. 
Multiresistant clone B23-ST131 has been 
previously associated with a high number of virulence 
genes [27,31]; in this work, the number of virulence 
genes associated with this clone was between five and 
eight. Regarding the clone D2-ST405, none of the 
antibiotic-resistant isolates could be classified as 
ExPEC (based on VS). Conversely, only a single 
isolate belonging to CGA was detected, which 
suggests that this group does not constitute a problem, 
at least within the studied hospitals. This isolate, 
however, harbored a large number (10) of virulence-
related genes. Accordingly, this ST69 isolate (HP21) 
along with isolates E38 and E69 (ST393 and ST38, 
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respectively) carried large numbers of virulence genes 
and were not disseminated. 
In this sense, the multiresistant clone B23-ST131 
could have reached an optimal balance between 
virulence and antibiotic resistance, allowing it to 
competitively colonize, to cause infection, and to 
disseminate among different hosts. 
On the other hand, we recently reported that a 
group of non-ExPEC E. coli isolates (based on VS) 
formed intracellular niches in urothelial cells; this 
finding was linked to the occurrence or recurrent UTIs 
[32]. Taking those findings into consideration, it is 
possible that the diversity of virulence-related genes in 
ExPEC is greater than the VS employed during the 
present study. 
With respect to ESBL production, this is the first 
study to show a clear predominance in our region of 
CTX-M-15 in E. coli strains (60%), followed by CTX-
M-2 (20%). Until recently, and particularly in 
Uruguay, the most frequently detected ESBL (in 
varying proportions) was CTX-M-2 [12,33]. CTX-M-
15 was first detected in 2006 in a general hospital [13], 
and in 2009, this ESBL was detected in the pediatric 
hospital [11]. However, until now, there was no 
information on the sequence types of ESBL-producing 
E. coli strains. The presence of CTX-M-15-producing 
pandemic clones such as ST131 and ST405 has 
already been reported in Colombia [10] and Argentina 
(ST131) [9]; nevertheless, there is no information 
about the sequence types associated with other CTX-
M enzymes in our continent. 
The CTX-M-9 and QnrA1-producing strain was 
typed as ST69, which has already been associated with 
ESBL and non-ESBL-producing strains [34,35]. In our 
study, this was the only isolate that belonged to CGA. 
Strains belonging to CGA have been widely reported 
around the world, even in South America [7,18]; 
nevertheless, in general, there is no information 
regarding sequence types of CGA strains.  
On the other hand, CTX-M-2-producing strains 
were associated with various sequence types, which 
included clones already linked to CTX-M enzymes 
such as ST38 and ST393 [25,34-36]. Furthermore, 
CTX-M-2 was detected in clones so far unrelated with 
antibiotic resistance, i.e., ST1158 (allelic profile 18, 3, 
17, 6, 5, 5, 4) and in the novel sequence type ST3627 
(allelic profile 13, 26, 39, 25, 5, 31, 19). Additionally, 
the isolate carrying qnrB/blaCTX-M-8 also belonged to 
the novel sequence type ST3555 (allelic profile 101, 
19, 97, 108, 26, 79, 19). 
CTX-M-8 was first described in Brazil in 2000, 
but was only recently detected in other South 
American countries including Uruguay and Argentina 
[9,11]. Additionally, this ESBL seems to be slowly 
disseminating in Europe, Africa, and Asia as well [37-
39].  
In our country, the dissemination of CTX-M-15 
may be the result of two mechanisms: either the 
dispersion of successful clones such as ST131 and 
ST405, or the acquisition of conjugative plasmids 
featuring multiple addiction systems. 
On the other hand, the expansion of blaCTX-M-14 
could be mainly due to cross-species dissemination of 
IncI1 plasmids featuring the pndAC addiction system. 
In this regard, we recently reported the occurrence of 
blaCTX-M-14 in an isolate of Salmonella enterica serovar 
Enteritidis, encoded in a similar plasmid [40]. 
Additionally, in our continent, IncI1 plasmids 
harboring blaCTX-M-14 and blaCTX-M-19 (both belonging 
to group 4 in the CTX-M family) have already been 
described in E. coli strains in our country and in 
Bolivia [14,36]. 
Furthermore, only one of the 11 isolates encoding 
blaCTX-M-2 carried such gene in a conjugative plasmid. 
Incidentally, such plasmid had no addiction systems. 
Recently, Bartoloni et al., in a 20-year study, 
reported a shift in the epidemiology of ESBLs in 
Bolivia and Perú, describing an increase in the 
prevalence of CTX-M-15 and CTX-M-14, and a 
decrease of CTX-M-2 [41]. A similar scenario was 
also described in Argentina [9]. 
 
Conclusions 
In this study, we propose some elements that could 
account for this epidemiologic change. For instance, 
the association of CTX-M-15 with successful clones 
or with plasmids carrying addiction systems, and/or 
the dissemination blaCTX-M-14 in conjugative IncI1 
plasmids with pndAC, contrasts with the small 
proportion of blaCTX-M-2-encoding conjugative 
plasmids lacking detectable addiction systems.  
Additionally, the link between CTX-M-15 (which 
confers higher resistance levels to ceftazidime) and 
PMQR such as aac(6’)Ib-cr, creates better chances for 
co-selection of those isolates carrying both resistance 
mechanisms, in relation to those carrying only CTX-
M-2. 
The fact that these changes in the epidemiology of 
ESBLs go hand in hand with changes in genes 
conferring resistance to other antimicrobials (such as 
PMQR) highlights the importance of molecular and 
epidemiological studies. 
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